Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News ArQule Inc. ARQL

Healthcare Biotechnology

Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ARQL)

ArQule To Report First Quarter 2016 Financial Results On May 4, 2016

GlobeNewswire April 20, 2016

ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016

GlobeNewswire April 5, 2016

Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma

GlobeNewswire March 22, 2016

ArQule Reports Fourth Quarter and Full Year 2015 Financial Results

GlobeNewswire February 29, 2016

ArQule Announces $15.3 Million Registered Direct Offering of Common Stock

GlobeNewswire February 29, 2016

ArQule to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

GlobeNewswire February 15, 2016

ArQule to Present at Upcoming Investor Conferences

GlobeNewswire February 4, 2016

ArQule Provides Proprietary Pipeline Update for AKT Inhibitors

GlobeNewswire January 28, 2016

ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium

GlobeNewswire January 25, 2016

ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087

GlobeNewswire December 15, 2015

ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib for Second-Line Hepatocellular Carcinoma

PR Newswire December 10, 2015

ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092

GlobeNewswire November 17, 2015

UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference

GlobeNewswire November 9, 2015

ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference

GlobeNewswire November 9, 2015

ArQule Reports Third Quarter 2015 Financial Results

GlobeNewswire November 4, 2015

ArQule to Present Data on Tivantinib, ARQ 087, ARQ 092, and ARQ 751 at AACR-NCI-EORTC Conference

GlobeNewswire October 27, 2015

ArQule to Report Third Quarter 2015 Financial Results on November 4, 2015

GlobeNewswire October 21, 2015

ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 and Next Generation AKT Inhibitor ARQ 751 in Oncology

GlobeNewswire October 15, 2015

ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference

GlobeNewswire September 28, 2015

ArQule to Present at Leerink Partners 4th Annual Rare Disease Roundtable on September 30, 2015

GlobeNewswire September 25, 2015